Ankit Alok Bagaria, Co-founder and CEO of Loopworm, published an opinion piece this week on insect biotech as India's next deep-tech opportunity. The article is ostensibly about silkworms and recombinant proteins. But buried in the third paragraph is a statement that every procurement manager in European cell culture should read carefully.

India's problem is not Europe's problem — but the underlying structural issue is identical. FBS is a raw material with inherently constrained supply, concentrated geography, and no synthetic substitute at commercial scale. The difference is that European labs have EU-origin FBS with full CEP documentation and TSE/BSE monitoring. What they do not have is immunity to supply disruption.

The FBS Supply Chain Reality in 2026

FBS is collected from bovine fetuses at licensed slaughter facilities. Supply is directly tied to cattle slaughter volumes, seasonal variation, and collection country regulations. Between 2020 and 2023, global FBS shortages caused significant disruption in cell culture workflows worldwide — price increases of 40–80% in some origin categories, extended lead times, and lot-to-lot variability that forced revalidation in GMP-adjacent environments.

That disruption happened without a geopolitical event specifically targeting a supply country. Drought in South America, changes in Brazilian export policy, or EU import restrictions on a major origin — any of these could replicate or exceed the 2020–2023 disruption within a single procurement cycle.

What Insect Biotech Actually Offers — and What It Doesn't Yet

Bagaria's article references the baculovirus expression vector system (BEVS) used in FDA-approved vaccines like Flublok. This is real and established technology. Insect cell lines — Sf9, Hi5, Sf21 — are routinely used in academic and pharmaceutical research for recombinant protein production, and BEVS is a validated GMP platform for specific applications.

What insect biotech does not replace in the next 3–5 years in standard cell culture and GMP manufacturing:

1. CAR-T and NK cell expansion — primary human T cells require human serum or defined xeno-free media. Insect-derived supplements are not a functional equivalent.
2. Hybridoma culture and mAb production — established protocols are deeply validated with FBS. Switching to alternative supplements requires full re-validation.
3. Viral vaccine production at commercial scale in Vero, MDCK and BHK-21 cell lines — FBS-based processes remain the norm for most production platforms outside dedicated BEVS workflows.
4. General mammalian cell culture R&D — the breadth of cell line compatibility, lot-to-lot data, and regulatory precedent for FBS is unmatched by any current alternative.

The insect biotech future Bagaria describes is real and coming. The timeline for it to meaningfully displace FBS in European GMP manufacturing is measured in decades, not years.

Two Practical Steps for Labs Today

Rather than waiting for the next generation of expression systems, labs can take two concrete steps now to reduce FBS-related risk:

1. Reduce FBS dependency where EMA already recommends it

EMA/410/01 explicitly discourages the use of bovine serum in advanced therapy medicinal product (ATMP) manufacturing. The guidance is not speculative — it reflects current regulatory expectation for CAR-T, NK cell, and MSC manufacturing processes heading toward Phase I/II clinical trials.

Human Serum Type AB Male Off-the-Clot is the established replacement for FBS in these workflows. It eliminates xenogenic immune reactions in the final cell product, provides a physiologically matched growth environment, and supports Ph. Eur. 5.2.12 ancillary material documentation. SeamlessBio supplies this product without minimum order quantity, with batch reservation, and with full GMP documentation on request.

2. Secure your FBS supply chain with batch reservation

For processes that remain FBS-dependent — which is the majority of cell culture workflows today — lot-to-lot consistency and supply security are the practical concerns. Once a cell line is validated on a specific FBS lot, changing lots requires re-validation. Mid-project lot changes are expensive, time-consuming, and often avoidable.

Batch reservation allows you to order a small test volume, validate it in your cell system, and then reserve the remaining lot for your project duration. SeamlessBio offers batch reservation for up to 6 weeks at no cost.

The Bigger Picture

Bagaria's article ends with a call for India to build proprietary biological platforms rather than remain a generic manufacturer dependent on foreign raw materials. It is a sound strategic argument — and one that applies to European cell culture labs in a quieter way.

Dependency on a single raw material with constrained geography, variable supply, and no short-term synthetic substitute is a process risk that can be managed. Not eliminated — managed. Batch reservation, dual sourcing, and switching to human serum for ATMP workflows are not transformative innovations. They are pragmatic decisions that reduce exposure to a supply chain vulnerability that Bagaria has described, from the Indian perspective, with unusual clarity.

The bugs are coming. Until they arrive at GMP scale, the question is whether your procurement strategy is prepared for the supply chain conditions that already exist.